Fast Facts : Chemotherapy Induced Neutropenia

An independent e-learning program, which uses CIN as a focused case-study to examine the use of biosimilars in supportive care in oncology.

Launch Date: 4/ 19/2021

Expiration Date: 4/19/2023

How to obtain CE credits:

Please note, you have to watch the entire video in order to receive any CE credit for this online activity.

Sign in or create a new account by clicking "Sign In" in top left corner. *If you previously participated in a CME activity accredited by IUSM  but do not know your password, please enter your email address and click on the 'Forget Your Password' link. Your password will be emailed to you.

1. Click the Tests tile > Launch SCORM to view the module.
2. After viewing the video go back to the Tests tile and click Post-Test to attest to completing the activity.
3. Click the MyCME button > Evaluations and Certificates
4. Find the activity name in the list and click Complete Evaluation.
5. Click Submit.
6. On the Evaluations and Certificates page, click Download Certificate or access your transcript through the Transcript tile.

1. Recall the definition of febrile neutropenia in patients receiving chemotherapy
2. Explain the impact of febrile neutropenia both for patient and the health system
3. Describe risk assessment tools for the development of serious complications
4. Contrast available treatment options for managing chemotherapy-induced neutropenia
5. Describe how G-CSF acts in the body to stimulate neutrophil production
6. Describe how G-CSFs are used prophylactically and in the management of chemotherapy-induced neutropenia
7. Set out the differences between short- and long-acting G-CSFs
8. State the guidelines for G-CSF use during the COVID-19 pandemic
9. Explain how biosimilars are developed and used
10. Describe how a biosimilar achieves the same outcomes for patients as its reference product
11. Discuss the beneficial impact of biosimilars in clinical practice

Commercial Support

This activity is supported by an educational grant from Fresenius Kabi.

References

1. Neutropenia. Cancer.Net. www.cancer.net/coping-with-cancer/physicalemotional-and-social-effects-cancer/managing-physical-sideeffects/neutropenia, last accessed November 2020.

 2. Cornes P, Gascon P, Vulto AG, Aapro M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs 2020;34:255–63.

3. Klastersky J, de Naurois J, Rolston K et al; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;27(suppl 5):v111–18.

4. National Comprehensive Cancer Network. Prevention and treatment of cancerrelated infections. v2.2020. NCCN Clinical Practice Guidelines in Oncology, 2020. nccn.org, last accessed October 2020.

 5. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 2014;90:190–9.

6. MASCC. Identifying patients at low risk for FN complications: development and validation of the MASCC Risk Index Score. www.mascc.org/mascc-fn-riskindex-score, last accessed October 2020.

7. Neutropenia. Cancer.Net. www.cancer.net/coping-with-cancer/physicalemotional-and-social-effects-cancer/managing-physical-sideeffects/neutropenia, last accessed November 2020.

8. Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol 2018;9:113.

9. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 2008;42:277–88.

10. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228– 37.

11. Carulli G. Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica 1997;82:606–16.

12. Bönig H, Silbermann S, Weller S et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)—results of a prospective randomised monocentre study. Bone Marrow Transplant 2001;28:259–64.

 13. American Society of Health-System Pharmacists (ASHP). AHFS Drug Information®: Filgrastim. www.drugs.com/monograph/filgrastim.html, last accessed October 2020.

14. Parker SD, Jacobs TF. Pegfilgrastim. [Updated 2020 Sep 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532893/.

15. American Society of Health-System Pharmacists (ASHP). AHFS Drug Information®: Pegfilgrastim. www.drugs.com/monograph/pegfilgrastim.html, last accessed October 2020.

16.National Comprehensive Cancer Network. Hematopoietic growth factors. v2.2020. NCCN Clinical Practice Guidelines in Oncology, 2020. nccn.org, last accessed October 2020.

17.National Comprehensive Cancer Network. Hematopoietic growth factors: shortterm recommendations specific to issues with COVID-19 (SARS-CoV-2). nccn.org, last accessed October 2020.

18.Cornes P, Gascon P, Chan S et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther 2018;35:1816–29.

19.Cornes P, Gascon P, Vulto AG, Aapro M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs 2020;34:255–63.

20.Fagnani D, Isa L, Verga MF et al. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study. Tumori 2014;100:491–8.

21. Cornes P, McBride A. Fast Facts: Biosimilars in Hematology and Oncology. Karger, 2020.

22. US Food and Drug Administration. Biosimilars. www.fda.gov/drugs/therapeuticbiologics-applications-bla/biosimilars, last accessed 4 November 2020.

23. US Food and Drug Administration. Biosimilar product: regulatory review and approval. www.fda.gov/media/108621/download, last accessed 19 November 2020.

24. US Food and Drug Administration. Biosimilar development, review, and approval. www.fda.gov/drugs/biosimilars/biosimilar-development-review-andapproval, last accessed 19 November 2020.

25. Gascon P, Krendyukov A, Mathieson N et al. Extrapolation in practice: lessons from 10 years with biosimilar filgrastim. BioDrugs 2019;33:635–45.

26. US Food and Drug Administration. Prescribing interchangeable products. www.fda.gov/drugs/biosimilars/prescribing-biosimilar-and-interchangeableproducts, last accessed 19 November 2020.

27. US Food and Drug Administration. Purple book. Database of licensed biological products. https://purplebooksearch.fda.gov/, last accessed 19 November 2020.

28. IMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, 2016.

29. Winegarden W. Promoting Biosimilar Competition to Reduce Patients’ Out-ofPocket Costs. Pacific Research Institute, 2020.

30.European Medicines Agency and European Council. Biosimilars in the EU; Information Guide for Healthcare Professionals. EMA, 2019.

31.Cornes P, Gascon P, Vulto AG, Aapro M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs 2020;34:255–63.

32.Soefje S. Considerations for adding biosimilars to formulary. Pharmacy Purchasing & Products 2019;16:14.

33. Janjigian YY, Bissig M, Curigliano G et al. Talking to patients about biosimilars. Future Oncology 2018;14:2403–14.

34.Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs 2020;34:407–14.

35.US Food and Drug Administration. Nonproprietary Naming of Biological Products: Guidance for Industry. FDA, 2017.

For questions about accessibility or to request accommodations please contact the IUSM CME office at 317-274-0104 or cme@iu.edu. One week advance notice will allow us to provide seamless access. Please ensure to specify the accommodations you need in order to participate.

This activity is supported by an educational grant from Fresenius Kabi .